Trial set to see if drug can prevent Alzheimer's

Trial set to see if drug can prevent alzheimer's
Many of the study participants are genetically prone to the disease.

(HealthDay) -- Researchers are preparing to test an experimental drug in people genetically primed to develop Alzheimer's disease.

The best-scenario hope is that the drug will lead to a way of preventing the progressive brain-wasting disease, and to a better understanding of its destructive processes, U.S. officials announced Tuesday.

The study volunteers will include some Americans as well as 300 members of an extended Colombian family -- some only 30 years old -- thought to have more relatives with Alzheimer's than any family in the world, The New York Times reported.

None of the will have any signs of dementia at the start of the five-year, $100 million study. Dr. Francis Collins, director of the U.S. National Institutes of Health, said this study is "the first to focus on people who are cognitively normal but at very high risk for Alzheimer's disease," according to the Times.

People with a certain genetic mutation are predestined to develop early-onset Alzheimer's. For this group, dementia typically sets in by about age 50, and signs of thinking and are evident by age 45.

It's hoped that the study will reveal clues to the development and treatment of Alzheimer's -- the leading cause of dementia -- in other people as well, not just those with what doctors call early-onset Alzheimer's.

The trial is designed to test the widely held theory that Alzheimer's is caused by a buildup in the brain of a protein called . The -- crenezumab, which is made by Genentech of South San Francisco -- is designed to attack the formation of beta .

Currently, there is no cure for Alzheimer's, which affects 5.4 million Americans, or one in eight . And as the ages, those numbers are expected to balloon, creating a major public health crisis in the United States.

Experts on Alzheimer's disease welcomed the announcement of the drug trial.

"This strategy is our best chance of success at Alzheimer's disease," said Dr. Sam Gandy, associate director of the Alzheimer's Disease Research Center at Mount Sinai School of Medicine and director of Mount Sinai's Center for Cognitive Health, in New York City.

"The main challenges are how to identify who is on their way to [Alzheimer's disease], how early we need to begin prior to symptoms, and how long we will have to run the trial before we can see whether the drug delays onset," added Gandy, chairman emeritus of the Alzheimer's Association's National Medical and Scientific Advisory Council.

More information: For more about Alzheimer's disease, visit the Alzheimer's Association.

Related Stories

Alzheimer’s prevention better than a cure

date Jul 14, 2011

In a new study published in Nature, Dr. Sam Gandy from Mount Sinai Medical Center argues that finding a cure for Alzheimer’s disease may be near impossible and that the best hope for researchers is to focus on preven ...

Falls may be early sign of Alzheimer's

date Jul 18, 2011

Falls and balance problems may be early indicators of Alzheimer’s disease, researchers at Washington University School of Medicine in St. Louis report July 17, 2011, at the Alzheimer’s Association International ...

Recommended for you

Helpful app for people with dementia

date Apr 21, 2015

Bangor University is providing expertise to support the development and effectiveness of 'Book of You', an 'app' being welcomed as having the potential to revolutionise reminiscence therapy for people with dementia.

New approaches for early diagnosis of Alzheimer's

date Apr 17, 2015

Mild cognitive impairment, or MCI, may be one of Alzheimer's earliest signs. The subtle changes of MCI include problems with memory, language, thinking and judgment and a subjective sense that mental function ...

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.